All News

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.

Data from the phase 3 ASTRUM-005 trial support the MHRA’s approval of serplulimab for patients with extensive-stage small cell lung cancer.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.

The Adventist Health Study found that patients who were vegetarians had a lower risk of medium-frequency cancers.

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.

PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

Detalimogene voraplasmid demonstrated a 71% any-time CR rate in this non-muscle invasive bladder cancer population in the phase 1/2 LEGEND trial.

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.

Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.

Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.

Among 77 enrolled patients, the cumulative incidence of grades 2 to 4 aGVHD at day 100 post-transplantation was 18.2% (95% CI, 10.6–27.6%).